JP2012519499A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012519499A5 JP2012519499A5 JP2011554111A JP2011554111A JP2012519499A5 JP 2012519499 A5 JP2012519499 A5 JP 2012519499A5 JP 2011554111 A JP2011554111 A JP 2011554111A JP 2011554111 A JP2011554111 A JP 2011554111A JP 2012519499 A5 JP2012519499 A5 JP 2012519499A5
- Authority
- JP
- Japan
- Prior art keywords
- patent document
- protein
- activity
- wild
- activated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 230000000368 destabilizing effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 1
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20948909P | 2009-03-09 | 2009-03-09 | |
| US61/209,489 | 2009-03-09 | ||
| PCT/US2010/026611 WO2010104821A1 (en) | 2009-03-09 | 2010-03-09 | Mirac proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015134811A Division JP6475112B2 (ja) | 2009-03-09 | 2015-07-03 | Ｍｉｒａｃタンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012519499A JP2012519499A (ja) | 2012-08-30 |
| JP2012519499A5 true JP2012519499A5 (enExample) | 2013-04-25 |
| JP6322785B2 JP6322785B2 (ja) | 2018-05-16 |
Family
ID=42728697
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011554111A Active JP6322785B2 (ja) | 2009-03-09 | 2010-03-09 | Ｍｉｒａｃタンパク質 |
| JP2015134811A Active JP6475112B2 (ja) | 2009-03-09 | 2015-07-03 | Ｍｉｒａｃタンパク質 |
| JP2018022055A Active JP6647330B2 (ja) | 2009-03-09 | 2018-02-09 | Ｍｉｒａｃタンパク質 |
| JP2020003446A Active JP7066761B2 (ja) | 2009-03-09 | 2020-01-14 | Ｍｉｒａｃタンパク質 |
| JP2022072982A Active JP7426433B2 (ja) | 2009-03-09 | 2022-04-27 | Ｍｉｒａｃタンパク質 |
| JP2024007215A Active JP7752710B2 (ja) | 2009-03-09 | 2024-01-22 | Ｍｉｒａｃタンパク質 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015134811A Active JP6475112B2 (ja) | 2009-03-09 | 2015-07-03 | Ｍｉｒａｃタンパク質 |
| JP2018022055A Active JP6647330B2 (ja) | 2009-03-09 | 2018-02-09 | Ｍｉｒａｃタンパク質 |
| JP2020003446A Active JP7066761B2 (ja) | 2009-03-09 | 2020-01-14 | Ｍｉｒａｃタンパク質 |
| JP2022072982A Active JP7426433B2 (ja) | 2009-03-09 | 2022-04-27 | Ｍｉｒａｃタンパク質 |
| JP2024007215A Active JP7752710B2 (ja) | 2009-03-09 | 2024-01-22 | Ｍｉｒａｃタンパク質 |
Country Status (18)
| Country | Link |
|---|---|
| US (9) | US20100260739A1 (enExample) |
| EP (2) | EP2406399B1 (enExample) |
| JP (6) | JP6322785B2 (enExample) |
| KR (6) | KR102265757B1 (enExample) |
| CN (3) | CN106008707A (enExample) |
| AU (1) | AU2010222818B2 (enExample) |
| BR (1) | BRPI1008971A2 (enExample) |
| CA (1) | CA2754056C (enExample) |
| CL (1) | CL2011002222A1 (enExample) |
| DK (1) | DK2406399T3 (enExample) |
| ES (1) | ES2661310T3 (enExample) |
| HK (1) | HK1218558A1 (enExample) |
| HU (1) | HUE036081T2 (enExample) |
| MX (4) | MX355507B (enExample) |
| NO (1) | NO2406399T3 (enExample) |
| PL (1) | PL2406399T3 (enExample) |
| PT (1) | PT2406399T (enExample) |
| WO (1) | WO2010104821A1 (enExample) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7629384B2 (en) * | 1997-09-17 | 2009-12-08 | Strategic Science & Technologies, Llc | Topical delivery of L-arginine to cause beneficial effects |
| US7914814B2 (en) * | 1997-09-17 | 2011-03-29 | Strategic Science & Technologies, Llc | Topical delivery of arginine of cause beneficial effects |
| US9226909B2 (en) | 2004-04-19 | 2016-01-05 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
| AU2005235308B2 (en) * | 2004-04-19 | 2011-12-01 | Strategic Science & Technologies, Llc | Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
| TWI395593B (zh) | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
| US20110229451A2 (en) * | 2009-03-06 | 2011-09-22 | Halozyme, Inc. | Temperature sensitive mutants of matrix metalloproteases and uses thereof |
| NO2406399T3 (enExample) | 2009-03-09 | 2018-07-14 | ||
| US12138268B2 (en) | 2009-06-24 | 2024-11-12 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| EP2445493A1 (en) | 2009-06-24 | 2012-05-02 | Strategic Science & Technologies, LLC | Topical composition containing naproxen |
| US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| EP2445492B1 (en) | 2009-06-24 | 2016-09-28 | Strategic Science & Technologies, LLC | Topical composition containing ibuprofen |
| CN103201293B (zh) | 2010-09-08 | 2016-04-27 | 哈洛齐梅公司 | 评估和鉴定或发展条件活性治疗蛋白的方法 |
| WO2012092523A1 (en) | 2010-12-29 | 2012-07-05 | Strategic Science & Technologies, Llc | Systems and methods for treatment of allergies and other indications |
| ES2811515T3 (es) | 2010-12-29 | 2021-03-12 | Strategic Science & Tech Llc | Tratamiento de disfunción eréctil y otras indicaciones |
| KR20150016579A (ko) | 2012-05-30 | 2015-02-12 | 추가이 세이야쿠 가부시키가이샤 | 표적 조직 특이적 항원 결합 분자 |
| JP2016530482A (ja) | 2013-05-23 | 2016-09-29 | アイフィノタイプ エルエルシー | ウェルネスを維持するか、または向上するための方法およびシステム |
| EP4610368A3 (en) | 2013-08-05 | 2025-11-05 | Twist Bioscience Corporation | De novo synthesized gene libraries |
| CN111304752B (zh) | 2013-12-04 | 2024-12-31 | 中外制药株式会社 | 抗原结合能力根据化合物的浓度而变化的抗原结合分子及其文库 |
| WO2015175375A1 (en) * | 2014-05-13 | 2015-11-19 | Short Jay M | Conditionally active biological proteins |
| US11111288B2 (en) | 2014-08-28 | 2021-09-07 | Bioatla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
| DK3186284T3 (da) * | 2014-08-28 | 2022-05-09 | Bioatla Inc | Betinget aktive kimæriske antigenreceptorer til modificerede t-celler |
| CA2959786A1 (en) * | 2014-09-03 | 2016-03-10 | Bioatla, Llc | Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts |
| AU2015335855A1 (en) | 2014-10-24 | 2017-05-18 | Mallinckrodt Hospital Products IP Limited | Method of treating patients with hepatorenal syndrome type 1 |
| US10669304B2 (en) | 2015-02-04 | 2020-06-02 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
| KR102790523B1 (ko) * | 2015-02-24 | 2025-04-02 | 바이오아트라, 인코퍼레이티드 | 조건부 활성 생체 단백질 |
| WO2016172377A1 (en) | 2015-04-21 | 2016-10-27 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
| JP2017014206A (ja) * | 2015-06-30 | 2017-01-19 | ナノアンティバイオティクス，インコーポレイテッド | 腹水の治療 |
| HK1258869A1 (zh) * | 2015-09-18 | 2019-11-22 | Twist Bioscience Corporation | 寡核酸变体文库及其合成 |
| US11512347B2 (en) | 2015-09-22 | 2022-11-29 | Twist Bioscience Corporation | Flexible substrates for nucleic acid synthesis |
| MX2018005063A (es) * | 2015-11-02 | 2018-12-10 | Bioatla Llc | Polipéptidos condicionalmente activos. |
| CN108603307A (zh) | 2015-12-01 | 2018-09-28 | 特韦斯特生物科学公司 | 功能化表面及其制备 |
| WO2017123537A1 (en) | 2016-01-12 | 2017-07-20 | Bioatla, Llc | Diagnostics using conditionally active antibodies |
| US10697972B2 (en) | 2016-01-12 | 2020-06-30 | Bioatla, Llc | Diagnostics using conditionally active antibodies |
| WO2020047527A2 (en) | 2018-09-02 | 2020-03-05 | F1 Bioventures, Llc | Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs |
| WO2017165245A2 (en) | 2016-03-19 | 2017-09-28 | F1 Oncology, Inc. | Methods and compositions for transducing lymphocytes and regulated expansion thereof |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| JP6735355B2 (ja) | 2016-04-15 | 2020-08-05 | バイオアトラ、エルエルシー | 抗Ａｘｌ抗体、抗体断片およびそれらの免疫コンジュゲートならびにそれらの使用 |
| TW202434312A (zh) | 2016-05-13 | 2024-09-01 | 美商拜奧亞特拉公司 | 抗-ror2抗體、抗體片段、其免疫結合物及其用途 |
| AU2017292936C1 (en) | 2016-07-08 | 2024-05-02 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| AU2017315294B2 (en) | 2016-08-22 | 2023-12-21 | Twist Bioscience Corporation | De novo synthesized nucleic acid libraries |
| AU2017320874B2 (en) * | 2016-08-31 | 2024-03-07 | Bioatla, Llc | Conditionally active polypeptides and methods of generating them |
| EP4664304A2 (en) | 2016-09-21 | 2025-12-17 | Atlas Data Storage, Inc. | Nucleic acid based data storage |
| AU2017378492B2 (en) | 2016-12-16 | 2022-06-16 | Twist Bioscience Corporation | Variant libraries of the immunological synapse and synthesis thereof |
| EP3565846A4 (en) * | 2017-01-03 | 2020-01-22 | Bioatla, LLC | PROTEIN THERAPEUTICS FOR THE TREATMENT OF SENESCENT CELLS |
| KR102630011B1 (ko) | 2017-01-11 | 2024-01-26 | 브리스톨-마이어스 스큅 컴퍼니 | Psgl-1 길항제 및 그의 용도 |
| MX2019008503A (es) | 2017-01-18 | 2019-09-13 | F1 Oncology Inc | Receptores de antigenos quimericos contra axl o ror2 y metodos de uso de los mismos. |
| CA3054303A1 (en) | 2017-02-22 | 2018-08-30 | Twist Bioscience Corporation | Nucleic acid based data storage |
| BR112019018288A2 (pt) | 2017-03-03 | 2020-03-31 | F1 Oncology, Inc. | Métodos e composições para transduzir e expandir linfócitos e regular a atividade dos mesmos |
| KR20240151866A (ko) | 2017-03-14 | 2024-10-18 | 파이브 프라임 테라퓨틱스, 인크. | 산성 pH에서 VISTA에 결합하는 항체 |
| CA3056388A1 (en) | 2017-03-15 | 2018-09-20 | Twist Bioscience Corporation | Variant libraries of the immunological synapse and synthesis thereof |
| KR102784398B1 (ko) | 2017-06-12 | 2025-03-19 | 트위스트 바이오사이언스 코포레이션 | 심리스 핵산 어셈블리를 위한 방법 |
| WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| CN111566125A (zh) | 2017-09-11 | 2020-08-21 | 特韦斯特生物科学公司 | Gpcr结合蛋白及其合成 |
| WO2019079769A1 (en) | 2017-10-20 | 2019-04-25 | Twist Bioscience Corporation | HEATED NANOWELLS FOR THE SYNTHESIS OF POLYNUCLEOTIDES |
| EP3720458A4 (en) | 2017-12-05 | 2021-12-08 | BioPlx, Inc. | METHODS AND COMPOSITIONS FOR PREVENTING MICROBIAL INFECTION |
| EP3735459A4 (en) | 2018-01-04 | 2021-10-06 | Twist Bioscience Corporation | DNA-BASED DIGITAL INFORMATION STORAGE |
| WO2019183040A1 (en) | 2018-03-21 | 2019-09-26 | Five Prime Therapeutics, Inc. | ANTIBODIES BINDING TO VISTA AT ACIDIC pH |
| IL278771B2 (en) | 2018-05-18 | 2025-09-01 | Twist Bioscience Corp | Polynucleotides, reagents and methods for nucleic acid hybridization |
| EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| CA3104536A1 (en) | 2018-07-11 | 2020-01-16 | Bristol-Myers Squibb Company | Antibodies binding to vista at acidic ph |
| WO2020032230A1 (ja) | 2018-08-10 | 2020-02-13 | 中外製薬株式会社 | 抗ｃｄ１３７抗原結合分子およびその使用 |
| CN112566929A (zh) * | 2018-08-21 | 2021-03-26 | 生物蛋白有限公司 | 具pH选择性的条件活性蛋白质 |
| EP3870600A1 (en) | 2018-10-24 | 2021-09-01 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| WO2020139871A1 (en) | 2018-12-26 | 2020-07-02 | Twist Bioscience Corporation | Highly accurate de novo polynucleotide synthesis |
| EP3930753A4 (en) | 2019-02-26 | 2023-03-29 | Twist Bioscience Corporation | VARIANT NUCLEIC ACID LIBRARIES FOR GLP1 RECEPTOR |
| WO2020176680A1 (en) | 2019-02-26 | 2020-09-03 | Twist Bioscience Corporation | Variant nucleic acid libraries for antibody optimization |
| CA3132840A1 (en) | 2019-03-08 | 2020-09-17 | Obsidian Therapeutics, Inc. | Human carbonic anhydrase 2 compositions and methods for tunable regulation |
| US12478674B2 (en) | 2019-04-18 | 2025-11-25 | Bristol-Myers Squibb Company | Ipilimumab variants with enhanced specificity for binding at low pH |
| EP3966227A1 (en) | 2019-05-07 | 2022-03-16 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| EP3972628A4 (en) | 2019-05-22 | 2023-01-18 | Biovie Inc. | TERLIPRESS INFORMATION |
| JP7387196B2 (ja) | 2019-06-11 | 2023-11-28 | バイオアトラ インコーポレイテッド | 条件付きで活性な抗ｅｐｃａｍ抗体、抗体フラグメント、それらのイムノコンジュゲート、及びそれらの使用 |
| EP3987019A4 (en) | 2019-06-21 | 2023-04-19 | Twist Bioscience Corporation | Barcode-based nucleic acid sequence assembly |
| JP2021032789A (ja) * | 2019-08-28 | 2021-03-01 | 国立大学法人信州大学 | ヒトの胸管リンパ液の流れの評価方法および評価具 |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| CN115023440B (zh) | 2019-09-23 | 2025-09-12 | 特韦斯特生物科学公司 | 结合CD3ε的抗体 |
| WO2021061829A1 (en) | 2019-09-23 | 2021-04-01 | Twist Bioscience Corporation | Variant nucleic acid libraries for crth2 |
| WO2022187289A1 (en) | 2021-03-01 | 2022-09-09 | Exuma Biotech Corp. | Methods and compositions for the delivery of retroviral particles |
| WO2023069892A1 (en) * | 2021-10-19 | 2023-04-27 | Short Jay M | Conditionally active proteins for neurodegenerative diseases |
| TW202342106A (zh) | 2022-02-09 | 2023-11-01 | 日商第一三共股份有限公司 | 環境應答性遮蔽抗體及其利用 |
| US20250099612A1 (en) | 2022-03-01 | 2025-03-27 | Exuma Biotech Corp. | Viral particles with membrane-bound hyaluronidase |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4318905A (en) | 1980-06-23 | 1982-03-09 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide agonists of luteinizing hormone releasing hormone containing heterocyclic amino acid residues |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US6054270A (en) | 1988-05-03 | 2000-04-25 | Oxford Gene Technology Limited | Analying polynucleotide sequences |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US5143854A (en) * | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5744101A (en) * | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5527681A (en) | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
| US5632957A (en) | 1993-11-01 | 1997-05-27 | Nanogen | Molecular biological diagnostic systems including electrodes |
| JPH05236997A (ja) | 1992-02-28 | 1993-09-17 | Hitachi Ltd | ポリヌクレオチド捕捉用チップ |
| US6045996A (en) * | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
| US6468742B2 (en) * | 1993-11-01 | 2002-10-22 | Nanogen, Inc. | Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip |
| US5965452A (en) | 1996-07-09 | 1999-10-12 | Nanogen, Inc. | Multiplexed active biologic array |
| IL107742A0 (en) * | 1993-11-24 | 1994-02-27 | Yeda Res & Dev | Chemically-modified binding proteins |
| US6335160B1 (en) * | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US5556752A (en) * | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US5830645A (en) | 1994-12-09 | 1998-11-03 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
| US5959098A (en) * | 1996-04-17 | 1999-09-28 | Affymetrix, Inc. | Substrate preparation process |
| US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
| EP0866853B1 (en) | 1995-12-07 | 2004-03-03 | Diversa Corporation | Method of screening for enzyme activity |
| US6764835B2 (en) | 1995-12-07 | 2004-07-20 | Diversa Corporation | Saturation mutageneis in directed evolution |
| US6022963A (en) | 1995-12-15 | 2000-02-08 | Affymetrix, Inc. | Synthesis of oligonucleotide arrays using photocleavable protecting groups |
| US6013440A (en) | 1996-03-11 | 2000-01-11 | Affymetrix, Inc. | Nucleic acid affinity columns |
| AU3568897A (en) | 1996-06-07 | 1998-01-05 | Eos Biotechnology, Inc. | Immobilised linear oligonucleotide arrays |
| US20070009930A1 (en) * | 1996-12-18 | 2007-01-11 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| CN1068524C (zh) * | 1997-06-23 | 2001-07-18 | 叶庆炜 | 一种治疗顽症牛皮癣的药物 |
| US6826296B2 (en) * | 1997-07-25 | 2004-11-30 | Affymetrix, Inc. | Method and system for providing a probe array chip design database |
| US20040091968A1 (en) | 1997-08-13 | 2004-05-13 | Short Jay M. | Recombinant phytases and methods of making and using them |
| WO1999009217A1 (en) | 1997-08-15 | 1999-02-25 | Hyseq, Inc. | Methods and compositions for detection or quantification of nucleic acid species |
| ES2260157T3 (es) | 1997-09-11 | 2006-11-01 | Bioventures, Inc., | Metodo para ser dispositivos de alta densidad. |
| US6465178B2 (en) * | 1997-09-30 | 2002-10-15 | Surmodics, Inc. | Target molecule attachment to surfaces |
| JP2002500040A (ja) * | 1998-01-12 | 2002-01-08 | コールド スプリング ハーバー ラボラトリー | 細胞の寿命の延長、方法および試薬 |
| IL137197A0 (en) | 1998-01-30 | 2001-07-24 | Cold Spring Harbor Lab | Modulation of cell proliferation, methods and reagents |
| EP1068356B8 (en) | 1998-04-03 | 2007-01-03 | Adnexus Therapeutics, Inc. | Addressable protein arrays |
| US6048695A (en) | 1998-05-04 | 2000-04-11 | Baylor College Of Medicine | Chemically modified nucleic acids and methods for coupling nucleic acids to solid support |
| NO315238B1 (no) | 1998-05-08 | 2003-08-04 | Gemvax As | Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy |
| US6277628B1 (en) * | 1998-10-02 | 2001-08-21 | Incyte Genomics, Inc. | Linear microarrays |
| JP2002530436A (ja) * | 1998-11-25 | 2002-09-17 | ジェネティカ インコーポレイテッド | 増殖能を増強しかつ複製老化を防止する方法及び試薬 |
| US6277489B1 (en) | 1998-12-04 | 2001-08-21 | The Regents Of The University Of California | Support for high performance affinity chromatography and other uses |
| US20090130718A1 (en) | 1999-02-04 | 2009-05-21 | Diversa Corporation | Gene site saturation mutagenesis |
| EP1092041A4 (en) | 1999-03-26 | 2001-09-19 | Diversa Corp | EXONUCLEASE-MEDIATED ASSEMBLY OF NUCLEIC ACIDS IN THE DIRECT EVOLUTION |
| US6221653B1 (en) * | 1999-04-27 | 2001-04-24 | Agilent Technologies, Inc. | Method of performing array-based hybridization assays using thermal inkjet deposition of sample fluids |
| US6653151B2 (en) | 1999-07-30 | 2003-11-25 | Large Scale Proteomics Corporation | Dry deposition of materials for microarrays using matrix displacement |
| US20010008765A1 (en) * | 1999-12-06 | 2001-07-19 | Fuji Photo Film Co., Ltd. | DNA chip and reactive solid carrier |
| CA2431600C (en) | 2000-12-12 | 2012-04-17 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US20030224444A1 (en) * | 2002-02-25 | 2003-12-04 | Sabbadini Roger A. | Antibodies to native conformations of membrane proteins |
| US20060141456A1 (en) * | 2002-06-12 | 2006-06-29 | Cynthia Edwards | Methods and compositions for milieu-dependent binding of a targeted agent to a target |
| WO2004035752A2 (en) * | 2002-10-15 | 2004-04-29 | Protein Design Labs, Inc. | ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS |
| US7285268B2 (en) * | 2002-11-26 | 2007-10-23 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
| JP2007521648A (ja) * | 2003-06-26 | 2007-08-02 | アール．ジェイ． メアーズ エルエルシー | バンド設計超格子を有するｍｏｓｆｅｔを有する半導体装置 |
| US20050260711A1 (en) * | 2004-03-30 | 2005-11-24 | Deepshikha Datta | Modulating pH-sensitive binding using non-natural amino acids |
| EP1778728A2 (en) * | 2004-08-19 | 2007-05-02 | Genentech, Inc. | Polypeptide variants with altered effector function |
| KR100754667B1 (ko) * | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물 |
| US8565901B2 (en) | 2006-07-05 | 2013-10-22 | Zoll Medical Corporation | Breakaway electrical connections for defibrillation electrode package |
| US20080131500A1 (en) * | 2006-12-04 | 2008-06-05 | The Board Of Regents Of The University Of Texas System | Methods and compositions for rapid inactivation of proteins |
| US20090181048A1 (en) | 2007-06-08 | 2009-07-16 | The Regents Of The University Of California | Cancer drug delivery using modified transferrin |
| PT2220239E (pt) | 2007-11-28 | 2015-09-01 | Bayer Cropscience Nv | Planta de brassica que compreende um alelo indeiscente mutante |
| CA2721052C (en) | 2008-04-11 | 2023-02-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| JP2011519279A (ja) | 2008-05-01 | 2011-07-07 | アムジエン・インコーポレーテツド | 抗ヘプシジン抗体及び使用の方法 |
| US8444976B2 (en) * | 2008-07-02 | 2013-05-21 | Argen-X B.V. | Antigen binding polypeptides |
| NO2406399T3 (enExample) | 2009-03-09 | 2018-07-14 | ||
| US20120022337A1 (en) | 2010-07-26 | 2012-01-26 | Searete Llc | MHC-less cells |
-
2010
- 2010-03-09 NO NO10751262A patent/NO2406399T3/no unknown
- 2010-03-09 BR BRPI1008971A patent/BRPI1008971A2/pt not_active Application Discontinuation
- 2010-03-09 MX MX2016016403A patent/MX355507B/es unknown
- 2010-03-09 JP JP2011554111A patent/JP6322785B2/ja active Active
- 2010-03-09 US US12/719,972 patent/US20100260739A1/en not_active Abandoned
- 2010-03-09 MX MX2012014655A patent/MX344312B/es unknown
- 2010-03-09 CN CN201610109229.8A patent/CN106008707A/zh active Pending
- 2010-03-09 KR KR1020197004366A patent/KR102265757B1/ko active Active
- 2010-03-09 CA CA2754056A patent/CA2754056C/en active Active
- 2010-03-09 DK DK10751262.6T patent/DK2406399T3/en active
- 2010-03-09 PL PL10751262T patent/PL2406399T3/pl unknown
- 2010-03-09 EP EP10751262.6A patent/EP2406399B1/en not_active Revoked
- 2010-03-09 KR KR1020117022908A patent/KR20110136825A/ko not_active Ceased
- 2010-03-09 CN CN201510493943.7A patent/CN105132395A/zh active Pending
- 2010-03-09 AU AU2010222818A patent/AU2010222818B2/en active Active
- 2010-03-09 KR KR1020177025147A patent/KR101838670B1/ko active Active
- 2010-03-09 ES ES10751262.6T patent/ES2661310T3/es active Active
- 2010-03-09 CN CN2010800114657A patent/CN102369296A/zh active Pending
- 2010-03-09 WO PCT/US2010/026611 patent/WO2010104821A1/en not_active Ceased
- 2010-03-09 MX MX2011009422A patent/MX338098B/es active IP Right Grant
- 2010-03-09 US US13/255,676 patent/US9464284B2/en active Active
- 2010-03-09 PT PT107512626T patent/PT2406399T/pt unknown
- 2010-03-09 KR KR1020217017001A patent/KR102455811B1/ko active Active
- 2010-03-09 KR KR1020227035375A patent/KR102618839B1/ko active Active
- 2010-03-09 EP EP17194268.3A patent/EP3282021A1/en not_active Ceased
- 2010-03-09 KR KR1020187006589A patent/KR101979188B1/ko active Active
- 2010-03-09 HU HUE10751262A patent/HUE036081T2/hu unknown
-
2011
- 2011-09-08 CL CL2011002222A patent/CL2011002222A1/es unknown
- 2011-09-08 MX MX2018004852A patent/MX2018004852A/es unknown
-
2012
- 2012-06-14 US US13/523,509 patent/US8709755B2/en active Active
-
2014
- 2014-03-04 US US14/196,950 patent/US9637734B2/en active Active
- 2014-08-20 US US14/464,059 patent/US9637735B2/en active Active
- 2014-09-11 US US14/483,980 patent/US9982252B2/en active Active
-
2015
- 2015-07-03 JP JP2015134811A patent/JP6475112B2/ja active Active
-
2016
- 2016-05-26 HK HK16106017.8A patent/HK1218558A1/zh unknown
- 2016-10-28 US US15/337,283 patent/US9994841B2/en active Active
-
2017
- 2017-09-08 US US15/699,543 patent/US11718844B2/en active Active
-
2018
- 2018-02-09 JP JP2018022055A patent/JP6647330B2/ja active Active
-
2020
- 2020-01-14 JP JP2020003446A patent/JP7066761B2/ja active Active
-
2022
- 2022-04-27 JP JP2022072982A patent/JP7426433B2/ja active Active
-
2023
- 2023-06-14 US US18/334,769 patent/US20230332135A1/en active Pending
-
2024
- 2024-01-22 JP JP2024007215A patent/JP7752710B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012519499A5 (enExample) | ||
| Kato et al. | Structure and engineering of the type III-E CRISPR-Cas7-11 effector complex | |
| Bezawork-Geleta et al. | LON is the master protease that protects against protein aggregation in human mitochondria through direct degradation of misfolded proteins | |
| Kelley et al. | Negative autoregulation mitigates collateral RNase activity of repeat-targeting CRISPR-Cas13d in mammalian cells | |
| Thitiananpakorn et al. | Association of mprF mutations with cross-resistance to daptomycin and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA) | |
| Maurer et al. | The assembly-activating protein promotes stability and interactions between AAV’s viral proteins to nucleate capsid assembly | |
| Mensa et al. | Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16 | |
| Anand et al. | Structure of oxalate decarboxylase from Bacillus subtilis at 1.75 Å resolution | |
| Vilfan et al. | Formation of native-like mammalian sperm cell chromatin with folded bull protamine | |
| Newton et al. | Phase separation of the LINE-1 ORF1 protein is mediated by the N-terminus and coiled-coil domain | |
| Dinh et al. | Induction of stress granule-like structures in vesicular stomatitis virus-infected cells | |
| Zhao et al. | Transcriptomic and metabolomics profiling of phage–host interactions between phage PaP1 and Pseudomonas aeruginosa | |
| Keane et al. | Functional transcriptional regulatory sequence (TRS) RNA binding and helix destabilizing determinants of murine hepatitis virus (MHV) nucleocapsid (N) protein | |
| Castelletto et al. | Structurally plastic peptide capsules for synthetic antimicrobial viruses | |
| Sanchez de Groot et al. | Evolutionary selection for protein aggregation | |
| Zhao et al. | An arginine finger regulates the sequential action of asymmetrical hexameric ATPase in the double-stranded DNA translocation motor | |
| Kang et al. | Structural basis for recognition and regulation of arenavirus polymerase L by Z protein | |
| Zhu et al. | Human TRA2A determines influenza A virus host adaptation by regulating viral mRNA splicing | |
| Winkelsas et al. | Targeting the 5′ untranslated region of SMN2 as a therapeutic strategy for spinal muscular atrophy | |
| Dorosz et al. | Molecular architecture of the Jumonji C family histone demethylase KDM5B | |
| Chew et al. | Anti‐dengue virus serotype 2 activity and mode of action of a novel peptide | |
| Wu-Chen et al. | Long-term exposure to food-grade disinfectants causes cross-resistance to antibiotics in Salmonella enterica serovar Typhimurium strains with different antibiograms and sequence types | |
| Liu et al. | Inhibition of base editors with anti-deaminases derived from viruses | |
| Zhong et al. | Transcriptomic analysis reveals the dependency of Pseudomonas aeruginosa genes for double-stranded RNA bacteriophage phiYY infection cycle | |
| Zaremba et al. | In vitro and in silico studies of the antiviral activity of polyhydrated fullerenes against influenza A (H1N1) virus |